Nausea was more frequent with tirzepatide vs placebo, especially with tirzepatide 15 mg (OR 5.60 [95% CI 3.12, 10.06]), associated with higher incidence of vomiting (OR 5.50 [95% CI 2.40, 12.59]) and diarrhoea (OR 3.31 [95% CI 1.40, 7.85])
doi: 10.3390/nu16010095, 21
Rarer issues like gallstones, pancreatitis, or gastroparesis can happen, though
Am Rev Respir Dis, 147(suppl): A113 (abstract)
Compared with antibody drugs and small molecule drugs, NADs are specifically favorable for personalized therapies owing to their strong specificity for diverse targets
Here's what they do: Suppress appetite centrally: GLP-1 acts on the hypothalamus, the brain's appetite control center, to reduce hunger and increase feelings of fullness [13]